# FDA 483 - Molecular PharmaGroup - December 11, 2023

Source: https://www.keypedia.com/records/483/molecular-pharmagroup/302fe2d2-ed08-4c5a-b31d-245b2174b3ef

> FDA 483 for Molecular PharmaGroup on December 11, 2023. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Molecular PharmaGroup
- Inspection Date: 2023-12-11
- Product Type: drugs
- Office Name: New Jersey District Office
- Summary: An FDA inspection of Molecular PharmaGroup, an outsourcing facility in New Providence, NJ, revealed two significant observations. The firm failed to include required information on its drug product labels, such as the facility's address and a list of ingredients. Additionally, Molecular PharmaGroup did not submit a report to the FDA identifying products compounded during a previous six-month period.

## Related Documents

- [483 - 2025-08-11](https://www.keypedia.com/records/483/molecular-pharmagroup/1f045f1f-5e0f-485f-8a7a-e3a374653183)

## Related Officers

- [Director of Clinical Training](https://www.keypedia.com/people/helen-verdel/f6caf5a8-74f5-4833-bd00-5579b369f4f9)

Company: https://www.keypedia.com/companies/molecular-pharmagroup/284f8e5d-cf64-49a4-80cb-59cd24428b20

Office: https://www.keypedia.com/offices/new-jersey-district-office/6ff5e2e9-5cff-44c7-af24-5a55329a8248